2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Clinical Procedures, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Immunology, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, Indolent Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3995 Metabolic acidosis independently predicts overall survival in multiple myeloma and captures at diagnosis prognostic information complementary to R-ISS

Ronin Joshua So Cosiquien, BS, Krishna Chaitanya Allam, BMsc2, Sai Anoop Dhamera, BS3, Hani Hassoun, MD4, Edgar Jaimes5, Abhijat Kitchlu6, Heather J. Landau, MD7, Ming Shen, BA8, Veronica Torres9, Sabine Karam, MD10
1 University of Minnesota, Minneapolis, Minnesota, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 University of Toronto, Toronto, Canada
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 University of Minnesota, Minneapolis, Minnesota, United States
9 University of Sao Paulo, Sao Paulo, Brazil
10 University of Minnesota, Minneapolis, Minnesota, United States

BACKGROUND

The Revised International Staging System (R-ISS) is the standard prognostic framework for newly diagnosed multiple myeloma (MM), yet host-level metabolic derangements that may contribute to survival heterogeneity within stages remain understudied. Metabolic acidosis is common at MM diagnosis — driven by light chain–mediated tubular injury and other mechanisms — but its independent prognostic significance after adjustment for renal function and tumor-biology-based staging has not been established. We investigated whether acidosis at diagnosis carries prognostic information independent of and complementary to R-ISS.

METHODS

In a single-center retrospective cohort of 293 patients with newly diagnosed MM (March 2009–January 2024, University of Minnesota; median follow-up 60.0 months), we evaluated overall survival (OS) from treatment initiation, censored at 5 years or December 31, 2025. Metabolic acidosis was defined as serum bicarbonate <22 mmol/L; renal impairment was defined per International Myeloma Working Group (IMWG) criteria (creatinine ≥2.0 mg/dL or eGFR ≤40 mL/min/1.73 m²). A multivariable Cox proportional hazards model assessed associations of metabolic acidosis, age, sex, renal impairment, diabetes, R-ISS stage, and IgA heavy chain status with OS. Missing data were addressed by multiple imputations by chained equations (MICE, 30 datasets) with Rubin's rules pooling. Sensitivity analyses substituted continuous eGFR for binary renal impairment and adjusted for autologous stem cell transplantation (ASCT). Hyponatremia (defined as < 130 mEq/L), hyperkalemia (defined as > 5 mEq/L), and anion gap were each tested as individual additions to the primary model to assess specificity. A 2-factor risk score (metabolic acidosis and diabetes: 0 vs. ≥1 factors) was compared with R-ISS by Harrell's concordance index (C-index) and Spearman correlation.

RESULTS

Among 293 patients (median age 65.0 years [IQR 58.0–71.0]; 62.1% male; 86.7% White; 65.9% ASCT recipients; 74 deaths [25.3%]), metabolic acidosis was present in 14.8% and diabetes in 12.0%. Metabolic acidosis was independently associated with inferior OS (HR 2.60, 95% CI 1.31–5.16; P = 0.007) after adjustment for all covariates. This association was not explained by graded renal dysfunction: acidosis remained significant when continuous eGFR replaced binary renal impairment (HR 2.46, 95% CI 1.24–4.79; P = 0.009), and bicarbonate correlated only moderately with eGFR (Pearson r = 0.42). Acidosis also remained significant after ASCT adjustment (HR 2.33, 95% CI 1.19–4.56; P = 0.014).

The prognostic signal was specific to acidosis: hyponatremia (P = 0.638), hyperkalemia (P = 0.623), and anion gap (P = 0.354) were not independently associated with OS, and anion gap did not outperform acidosis when substituted for it (HR 1.08, P = 0.177 vs. HR 2.60, P = 0.007). Other covariates independently associated with OS included diabetes (HR 2.69, 95% CI 1.51–4.79; P = 0.001), R-ISS stage (HR 1.96 per stage, 95% CI 1.32–2.91; P = 0.001), IgA heavy chain (HR 1.94, 95% CI 1.16–3.25; P = 0.013), and age (HR 1.05 per year, 95% CI 1.03–1.08; P < 0.001). Renal impairment was not independently significant (HR 0.63, 95% CI 0.32–1.25; P = 0.179). Full model discrimination was good (C-index 0.736).

A 2-factor stratification using acidosis and diabetes (≥1 vs. 0 factors) yielded an unadjusted HR of 2.57 (95% CI 1.57–4.19; P < 0.001), with pooled 3-year OS of 70.2% (95% CI 57.6–79.7%) versus 84.4% (95% CI 78.6–88.8%). This score was minimally correlated with R-ISS (Spearman ρ = 0.069), and a combined model improved discrimination beyond either alone (C-index 0.658 vs. 0.604 for R-ISS and 0.603 for the 2-factor score individually).

CONCLUSIONS

Metabolic acidosis at diagnosis is independently associated with inferior OS in newly diagnosed MM — an association that persists after adjustment for renal function, R-ISS stage, and other established prognostic factors, and is not explained by graded renal dysfunction. The near-zero correlation between a simple metabolic risk score incorporating acidosis and R-ISS, together with improved discrimination when combined, suggests that acidosis captures prognostic information independent of tumor-biology-based staging. External validation is warranted to determine whether this readily available biomarker can improve risk stratification in MM.

Ronin Joshua So Cosiquien, BS: No relevant conflicts of interest to declare.